Sareum Holdings discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. The Company's drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate. Sareum Holdings develops therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The Company’s product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, TYK2 kinase-autoimmune diseases and TYK2 kinase-cancer.